MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Navidea Biopharmaceuticals DIO Ratio 2011-2026 | NAVB
Annual DIO Ratio Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.4 K | - | 59.1 K | - | - | - | 234 | 136 | 215 | 2.45 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59.1 K | 136 | 19.4 K |
Quarterly DIO Ratio Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 16.2 K | 61.6 K | - | - | - | - | - | - | 189 K | 43.4 K | 12.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 189 K | 12.7 K | 64.6 K |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agenus
AGEN
|
0.163 | $ 3.64 | 9.31 % | $ 108 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
1.74 K | $ 35.08 | -0.36 % | $ 2.03 B | USA |
 |
Akebia Therapeutics
AKBA
|
147 | $ 1.39 | 0.36 % | $ 357 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.5 | $ 331.14 | 3.85 % | $ 43.4 B | USA |
 |
Amgen
AMGN
|
200 | $ 344.03 | -1.12 % | $ 185 B | USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amneal Pharmaceuticals
AMRX
|
117 | $ 12.27 | -1.68 % | $ 3.85 B | USA |
 |
Anika Therapeutics
ANIK
|
247 | $ 14.99 | 1.28 % | $ 220 M | USA |
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
181 | $ 73.8 | -0.55 % | $ 1.43 B | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.88 | -5.16 % | $ 4.8 M |  China |
 |
Aquestive Therapeutics
AQST
|
120 | $ 4.12 | -0.24 % | $ 441 M | USA |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M |  Canada |
 |
Ardelyx
ARDX
|
989 | $ 5.99 | 0.84 % | $ 1.44 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
185 | $ 24.06 | 1.82 % | $ 3.06 B | USA |